## **IN THE SPECIFICATION:**

Please insert the following paragraph on page 1 after the Title:

This application is a §371 National Stage application of PCT/US2004/013787, filed on May 3, 2004, which claims priority from: U.S. Provisional Application No. 60/468,579 filed May 7, 2003.

#### IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Original) A method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation comprising administering a therapeutically effective amount of a compound of structural formula I:

$$\begin{array}{c|c}
R^3 \\
N-X-R^2 \\
R^5 \\
R^4
\end{array}$$

wherein:

"a" and "b" are independently selected from a single bond and a double bond;

X is selected from:

- (A) -C(O)-,
- (B) -C(O)-O-,
- (C)  $-C(O)-N(R^7)$ -,and
- (D)  $-S(O)_{n}$ -;

R<sup>1</sup> is selected from:

- (A)  $C_{1-3}$  alkyl,
- (B) C<sub>2-3</sub> alkenyl,
- (C) C<sub>3-6</sub> cycloalkyl,

Case No.: 20880P

Page 3

- (D) C<sub>1-3</sub> alkyl wherein one or more of the hydrogen atoms has been replaced with a fluorine atom,
- (E) aryl, and
- (F) aryl-C<sub>1-3</sub> alkyl;

## R<sup>2</sup> is selected from:

- (A) aryl, either unsubstituted or substituted with one to three substituents selected from:
  - (1) halogen,
  - (2) aryl,
  - (3) C<sub>1-8</sub> alkyl,
  - (4) C<sub>3-8</sub> cycloalkyl,
  - (5) C<sub>3-8</sub> cycloheteroalkyl,
  - (6) aryl C<sub>1</sub>-6alkyl,
  - (7) amino C<sub>0</sub>-6alkyl,
  - (8) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
  - (9) (C<sub>1-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
  - (10) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
  - (11) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
  - (12) C<sub>1-6</sub> alkylthio,
  - (13) aryl C<sub>0-6</sub>alkylthio,
  - (14) C<sub>1-6</sub> alkylsulfinyl,
  - (15) aryl C<sub>0-6</sub>alkylsulfinyl,
  - (16) C<sub>1-6</sub> alkylsulfonyl,
  - (17) aryl C<sub>0-6</sub>alkylsulfonyl,
  - (18) C<sub>1-6</sub> alkoxy C<sub>0-6</sub>alkyl,
  - (19) aryl C<sub>0-6</sub> alkoxy C<sub>0-6</sub>alkyl,
  - (20) hydroxycarbonyl C<sub>0-6</sub>alkyl,
  - (21) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
  - (22) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
  - (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
  - (24) hydroxy C<sub>0</sub>-6alkyl,
  - (25) cyano,
  - (26) nitro,
  - (27) perfluoroC<sub>1</sub>-4alkyl,

Case No.: 20880P

- (28) perfluoroC<sub>1</sub>-4alkoxy,
- (29) C<sub>1-6</sub> alkylcarbonyloxy,
- (30) aryl C<sub>0</sub>-6alkylcarbonyloxy,
- (31) alkyl C<sub>1-6</sub> carbonylamino,
- (32) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (33) C<sub>1-6</sub> alkylsulfonylamino,
- (34) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (35) C<sub>1-6</sub> alkoxycarbonylamino,
- (36) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (37) C<sub>1-6</sub>alkylaminocarbonylamino,
- (38) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (39) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (40) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (42) C<sub>0-6</sub> alkyl carbonyl C<sub>0-6</sub> alkyl,
- (43) aryl C<sub>0-6</sub> alkyl carbonyl C<sub>0-6</sub> alkyl, and
- (44) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy;
- (B) C<sub>1-8</sub> alkyl, unsubstituted or substituted with one to three substituents independently selected from:
  - (1) halogen,
  - (2)  $C_{1-8}$  alkyl,
  - (3) C<sub>3-8</sub> cycloalkyl,
  - (4) C<sub>3-8</sub> cycloheteroalkyl,
  - (5) amino,
  - (6) C<sub>1-6</sub> alkylamino,
  - (7)  $(C_{1-6} \text{ alkyl})_{2}$ amino,
  - (8) aryl C<sub>0-6</sub> alkylamino,
  - (9) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino,
  - (10)  $C_{1-6}$  alkylthio,
  - (11) aryl C<sub>0-6</sub>alkylthio,
  - (12) C<sub>1-6</sub> alkylsulfinyl,
  - (13) aryl C<sub>0</sub>-6alkylsulfinyl,
  - (14) C<sub>1-6</sub> alkylsulfonyl,
  - (15) aryl C<sub>0-6</sub>alkylsulfonyl,

Case No.: 20880P

- (16)  $C_{1-6}$  alkoxy,
- (17) aryl C<sub>0-6</sub> alkoxy,
- (18) hydroxycarbonyl,
- (19) C<sub>1-6</sub> alkoxycarbonyl,
- (20) aryl C<sub>0-6</sub> alkoxycarbonyl,
- (21) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (22) hydroxy,
- (23) cyano,
- (24) nitro,
- (25) perfluoroC<sub>1-4</sub>alkyl,
- (26) perfluoroC<sub>1-4</sub>alkoxy,
- (27) oxo,
- (28) C<sub>1-6</sub> alkylcarbonyloxy,
- (29) aryl C<sub>0-6</sub>alkylcarbonyloxy,
- (30) alkyl C<sub>1-6</sub> carbonylamino,
- (31) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (32) C<sub>1-6</sub> alkylsulfonylamino,
- (33) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (34) C<sub>1-6</sub> alkoxycarbonylamino,
- (35) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (36) C<sub>1</sub>-6alkylaminocarbonylamino,
- (37) aryl C<sub>0-6</sub>alkylaminocarbonylamino,
- (38) (C<sub>1</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (39) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (41) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy, and
- (42) spiro-C3-8cycloalkyl;
- (C) perfluoroC<sub>1-6</sub> alkyl,
- (D) aryl-C<sub>1-6</sub> alkyl-, wherein aryl is unsubstituted or substituted with 1 to 3 substituents independently selected from:
  - (1) halogen,
  - (2) C1-8 alkyl,
  - (3) C<sub>3-8</sub> cycloalkyl,
  - (4) aryl,

- (5) aryl C<sub>1-3</sub> alkyl-,
- (6) amino,
- (7)  $amino C_{1-6} alkyl-$ ,
- (8) C<sub>1-3</sub> acylamino,
- (9)  $C_{1-3}$  acylamino  $C_{1-6}$  alkyl,
- (10) C<sub>1-6</sub> alkylamino,
- (11)  $C_{1-6}$  alkylamino  $C_{1-6}$  alkyl,
- (12)  $di(C_{1-6})$  alkylamino,
- (13)  $di(C_{1-6})$  alkylamino- $C_{1-6}$  alkyl,
- (14)  $C_{1-4}$  alkoxy,
- (15)  $C_{1-4}$  alkylthio,
- (16) C<sub>1-4</sub> alkylsulfinyl,
- (17)  $C_{1-4}$  alkylsulfonyl,
- (18)  $C_{1-4}$  alkoxy  $C_{1-6}$  alkyl,
- (19) hydroxycarbonyl,
- (20) hydroxycarbonyl C<sub>1-6</sub> alkyl,
- (21) C<sub>1-5</sub> alkoxycarbonyl,
- (22) C<sub>1-3</sub> alkoxycarbonyl C<sub>1-6</sub> alkyl,
- (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (24) hydroxy,
- (25) hydroxy  $C_{1-6}$  alkyl,
- (26) cyano,
- (27) nitro,
- (28) trifluoromethyl,
- (29) trifluoromethoxy,
- (30) C<sub>1-5</sub> alkylcarbonyloxy;

and wherein alkyl is substituted with one to three substituents selected from:

- (1) halogen,
- (2) C<sub>3-8</sub> cycloalkyl,
- (3) C<sub>3-8</sub> cycloheteroalkyl,
- (4) amino,
- (5) C<sub>1-6</sub> alkylamino,
- (6) (C<sub>1-6</sub> alkyl)2amino,
- (7) aryl C<sub>0-6</sub> alkylamino,

Case No.: 20880P

- (8) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino,
- (9) C<sub>1-6</sub> alkylthio,
- (10) aryl C<sub>0-6</sub> alkylthio,
- (11) C<sub>1-6</sub> alkylsulfinyl,
- (12) aryl C<sub>0</sub>-6alkylsulfinyl,
- (13) C<sub>1-6</sub> alkylsulfonyl,
- (14) aryl C<sub>0-6</sub> alkylsulfonyl,
- (15)  $C_{1-6}$  alkoxy,
- (16) aryl C<sub>0-6</sub> alkoxy,
- (17) hydroxycarbonyl,
- (18) C<sub>1-6</sub> alkoxycarbonyl,
- (19) aryl C<sub>0-6</sub> alkoxycarbonyl,
- (20) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (21) hydroxy,
- (22) cyano,
- (23) nitro,
- (24) trifluoroalkyl,
- (25) trifluoroalkoxy,
- (26) oxo,
- (27) C<sub>1-6</sub> alkylcarbonyloxy,
- (28) aryl C<sub>0-6</sub> alkylcarbonyloxy,
- (29) C<sub>1-6</sub> alkyl carbonylamino,
- (30) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (31) C<sub>1-6</sub> alkylsulfonylamino,
- (32) aryl C<sub>0-6</sub> alkylsulfonylamino,
- (33) C<sub>1-6</sub> alkoxycarbonylamino,
- (34) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (35) C<sub>1-6</sub> alkylaminocarbonylamino,
- (36) aryl C<sub>0-6</sub> alkylaminocarbonylamino,
- (37) (C<sub>1-6</sub> alkyl)<sub>2</sub> aminocarbonylamino,
- (38) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub> aminocarbonylamino,
- (39) (C<sub>1-6</sub> alkyl)<sub>2</sub> aminocarbonyloxy,
- (40) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub> aminocarbonyloxy, and
- (41) spiro-C<sub>3-8</sub> cycloalkyl;

Case No.: 20880P

- (E) C<sub>2-8</sub> alkenyl, unsubstituted or substituted with one to three substituents independently selected from:
  - (1) halogen,
  - (2)  $C_{1-8}$  alkyl,
  - (3) C<sub>3-8</sub> cycloalkyl,
  - (4) C<sub>3-8</sub> cycloheteroalkyl,
  - (5) amino,
  - (6) C<sub>1-6</sub> alkylamino,
  - (7)  $(C_{1-6} \text{ alkyl})_2 \text{amino}$ ,
  - (8) aryl C<sub>0-6</sub> alkylamino,
  - (9) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino,
  - (10)  $C_{1-6}$  alkylthio,
  - (11) aryl C<sub>0</sub>-6alkylthio,
  - (12) C<sub>1-6</sub> alkylsulfinyl,
  - (13) aryl C<sub>0</sub>-6alkylsulfinyl,
  - (14) C<sub>1-6</sub> alkylsulfonyl,
  - (15) aryl C<sub>0</sub>-6alkylsulfonyl,
  - (16)  $C_{1-6}$  alkoxy,
  - (17) aryl C<sub>0-6</sub> alkoxy,
  - (18) hydroxycarbonyl,
  - (19) C<sub>1-6</sub> alkoxycarbonyl,
  - (20) aryl C<sub>0-6</sub> alkoxycarbonyl,
  - (21) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
  - (22) hydroxy,
  - (23) cyano,
  - (24) nitro,
  - (25) perfluoroC<sub>1-4</sub>alkyl,
  - (26) perfluoroC<sub>1</sub>-4alkoxy,
  - (27) oxo,
  - (28) C<sub>1-6</sub> alkylcarbonyloxy,
  - (29) aryl C<sub>0-6</sub>alkylcarbonyloxy,
  - (30) alkyl C<sub>1-6</sub> carbonylamino,
  - (31) aryl C<sub>0-6</sub> alkylcarbonylamino,
  - (32) C<sub>1-6</sub> alkylsulfonylamino,

Case No.: 20880P

- (33) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (34) C<sub>1-6</sub> alkoxycarbonylamino,
- (35) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (36) C<sub>1-6</sub>alkylaminocarbonylamino,
- (37) aryl C<sub>0-6</sub>alkylaminocarbonylamino,
- (38) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (39) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (41) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy, and
- (42) spiro-C3-8cycloalkyl;
- (F) aryl C<sub>2-8</sub> alkenyl, wherein aryl is unsubstituted or substituted with one to three substituents independently selected from:
  - (1) halogen,
  - (2)  $C_{1-8}$  alkyl,
  - (3) C<sub>3-8</sub> cycloalkyl,
  - (4) aryl,
  - (5)  $aryl C_{1-3} alkyl-$ ,
  - (6) amino,
  - (7)  $amino C_{1-6}$  alkyl-,
  - (8) C<sub>1-3</sub> acylamino,
  - (9) C<sub>1-3</sub> acylamino C<sub>1-6</sub> alkyl,
  - (10) C<sub>1-6</sub> alkylamino,
  - (11) C<sub>1-6</sub> alkylamino C<sub>1-6</sub> alkyl,
  - (12) di(C<sub>1-6</sub>) alkylamino,
  - (13)  $di(C_{1-6})$  alkylamino- $C_{1-6}$  alkyl,
  - (14) C<sub>1-4</sub> alkoxy,
  - (15)  $C_{1-4}$  alkylthio,
  - (16) C<sub>1-4</sub> alkylsulfinyl,
  - (17) C<sub>1-4</sub> alkylsulfonyl,
  - (18)  $C_{1-4}$  alkoxy  $C_{1-6}$  alkyl,
  - (19) hydroxycarbonyl,
  - (20) hydroxycarbonyl C<sub>1-6</sub> alkyl,
  - (21) C<sub>1-5</sub> alkoxycarbonyl,
  - (22) C<sub>1-3</sub> alkoxycarbonyl C<sub>1-6</sub> alkyl,

Case No.: 20880P

- (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (24) hydroxy,
- (25) hydroxy C<sub>1-6</sub> alkyl,
- (26) cyano,
- (27) nitro,
- (28) trifluoromethyl,
- (29) trifluoromethoxy, and
- (30) C<sub>1-5</sub> alkylcarbonyloxy;
- (G) C<sub>3-8</sub> cycloalkyl, either unsubstituted or substituted with one to 3 substituents selected from:
  - (1) halogen,
  - (2) aryl,
  - (3)  $C_{1-8}$  alkyl,
  - (4) C<sub>3-8</sub> cycloalkyl,
  - (5) C<sub>3-8</sub> cycloheteroalkyl,
  - (6) aryl C<sub>1-6</sub>alkyl,
  - (7) amino C<sub>0-6</sub>alkyl,
  - (8) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
  - (9) (C<sub>1-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
  - (10) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
  - (11) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
  - (12)  $C_{1-6}$  alkylthio,
  - (13) aryl C<sub>0</sub>-6alkylthio,
  - (14) C<sub>1-6</sub> alkylsulfinyl,
  - (15) aryl C<sub>0-6</sub>alkylsulfinyl,
  - (16) C<sub>1-6</sub> alkylsulfonyl,
  - (17) aryl C<sub>0</sub>-6alkylsulfonyl,
  - (18) C<sub>1-6</sub> alkoxy C<sub>0-6</sub>alkyl,
  - (19) aryl C<sub>0-6</sub> alkoxy C<sub>0-6</sub>alkyl,
  - (20) hydroxycarbonyl C<sub>0-6</sub>alkyl,
  - (21) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
  - (22) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
  - (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
  - (24) hydroxy C<sub>0-6</sub>alkyl,

Case No.: 20880P

- (25) cyano,
- (26) nitro,
- (27) perfluoroC<sub>1-4</sub>alkyl,
- (28) perfluoroC<sub>1-4</sub>alkoxy,
- (29) oxo,
- (30) C<sub>1-6</sub> alkylcarbonyloxy,
- (31) aryl C<sub>0</sub>-6alkylcarbonyloxy,
- (32) alkyl C<sub>1-6</sub> carbonylamino,
- (33) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (34) C<sub>1-6</sub> alkylsulfonylamino,
- (35) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (36) C<sub>1-6</sub> alkoxycarbonylamino,
- (37) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (38) C<sub>1-6</sub>alkylaminocarbonylamino,
- (39) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (42) (C<sub>1</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy,
- (43) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy,
- (44) C<sub>0-6</sub> alkylcarbonly C<sub>0-6</sub> alky, and
- (45) spiro-C3-8cycloalkyl;
- (H) cycloheteroalkyl, unsubstituted or substituted with one to three substituents selected from:
  - (1) halogen,
  - (2) aryl,
  - (3)  $C_{1-8}$  alkyl,
  - (4) C<sub>3-8</sub> cycloalkyl,
  - (5) C<sub>3-8</sub> cycloheteroalkyl,
  - (6) aryl C<sub>1</sub>-6alkyl,
  - (7) amino C<sub>0</sub>-6alkyl,
  - (8) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
  - (9) (C<sub>1-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
  - (10) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
  - (11) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,

PCT/US2004/013787 Case No.: 20880P

Page 12

(12) C<sub>1-6</sub> alkylthio,

- (13) aryl C<sub>0</sub>-6alkylthio,
- (14) C<sub>1-6</sub> alkylsulfinyl,
- (15) aryl C<sub>0</sub>-6alkylsulfinyl,
- (16) C<sub>1-6</sub> alkylsulfonyl,
- (17) aryl C<sub>0</sub>-6alkylsulfonyl,
- (18) C<sub>1-6</sub> alkoxy C<sub>0-6</sub>alkyl,
- (19) aryl C<sub>0-6</sub> alkoxy C<sub>0-6</sub>alkyl,
- (20) hydroxycarbonyl C<sub>0-6</sub>alkyl,
- (21) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (22) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (24) hydroxy C<sub>0</sub>-6alkyl,
- (25) cyano,
- (26) nitro,
- (27) perfluoroC<sub>1-4</sub>alkyl,
- (28) perfluoroC<sub>1</sub>-4alkoxy,
- (29) oxo,
- (30) C<sub>1-6</sub> alkylcarbonyloxy,
- (31) aryl C<sub>0-6</sub>alkylcarbonyloxy,
- (32) alkyl C<sub>1-6</sub> carbonylamino,
- (33) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (34) C<sub>1-6</sub> alkylsulfonylamino,
- (35) aryl C<sub>0-6</sub>alkylsulfonylamino,
- (36) C<sub>1-6</sub> alkoxycarbonylamino,
- (37) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (38) C<sub>1-6</sub>alkylaminocarbonylamino,
- (39) aryl C<sub>0-6</sub>alkylaminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (42) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (43) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy, and
- (44) spiro-C3-8cycloalkyl;

Case No.: 20880P Page 13

provided that any heteroatom substituent is bonded to a carbon atom in the cycloheteroalkyl ring;

 $R^3$  is selected from H, perfluoro  $C_{1-8}$  alkyl, and  $C_{1-8}$  alkyl, unsubstituted or substituted with one to three halogen atoms, or  $R^2$  and  $R^3$ , together with the nitrogen atom, and the "X" moiety to which they are attached, form a 5- to 7-membered heterocyclic ring, optionally containing one or two additional heteroatoms selected from N, S, and O, optionally having one or more degrees of unsaturation, optionally fused to a 6-membered heteroaromatic or aromatic ring, either unsubstituted or substituted with one to three substituents selected from:

- (1) halogen,
- (2) aryl,
- (3)  $C_{1-8}$  alkyl,
- (4) C<sub>3-8</sub> cycloalkyl,
- (5) C<sub>3-8</sub> cycloheteroalkyl,
- (6) aryl C<sub>1</sub>-6alkyl,
- (7) amino C<sub>0</sub>-6alkyl,
- (8) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (9) (C<sub>1-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (10) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (11) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (12)  $C_{1-6}$  alkylthio,
- (13) aryl C<sub>0</sub>-6alkylthio,
- (14) C<sub>1-6</sub> alkylsulfinyl,
- (15) aryl C<sub>0-6</sub>alkylsulfinyl,
- (16) C<sub>1-6</sub> alkylsulfonyl,
- (17) aryl C<sub>0</sub>-6alkylsulfonyl,
- (18)  $C_{1-6}$  alkoxy  $C_{0-6}$ alkyl,
- (19) aryl C<sub>0-6</sub> alkoxy C<sub>0-6</sub>alkyl,
- (20) hydroxycarbonyl C<sub>0-6</sub>alkyl,
- (21) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (22) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (24) hydroxy C<sub>0</sub>-6alkyl,
- (25) cyano,
- (26) nitro,

Case No.: 20880P

Page 14

- (27) perfluoroC<sub>1-4</sub>alkyl,
- (28) perfluoroC<sub>1</sub>-4alkoxy,
- (29) oxo,
- (30) C<sub>1-6</sub> alkylcarbonyloxy,
- (31) aryl C<sub>0</sub>-6alkylcarbonyloxy,
- (32) C<sub>1-6</sub> alkyl carbonylamino,
- (33) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (34) C<sub>1-6</sub> alkylsulfonylamino,
- (35) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (36) C<sub>1-6</sub> alkoxycarbonylamino,
- (37) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (38) C<sub>1-6</sub>alkylaminocarbonylamino,
- (39) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (42) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (43) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy, and
- (44) spiro-C3-8cycloalkyl, provided that any heteroatom substituent is bonded to a carbon atom in the heterocyclic ring;

## R<sup>4</sup> and R<sup>5</sup> are each independently selected from

- (1) hydrogen,
- (2) halogen,
- (3) aryl,
- (4) C<sub>1-8</sub> alkyl,
- (5) C<sub>3-8</sub> cycloalkyl,
- (6) C<sub>3-8</sub> cycloheteroalkyl,
- (7) aryl C<sub>1</sub>-6alkyl,
- (8) amino C<sub>0</sub>-6alkyl,
- (9) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (10) (C<sub>1-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (11) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (12) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (13)  $C_{1-6}$  alkylthio,

Case No.: 20880P

Page 15

- (14) aryl C<sub>0</sub>-6alkylthio,
- (15) C<sub>1-6</sub> alkylsulfinyl,
- (16) aryl C<sub>0</sub>-6alkylsulfinyl,
- (17) C<sub>1-6</sub> alkylsulfonyl,
- (18) aryl C<sub>0-6</sub>alkylsulfonyl,
- (19)  $C_{1-6}$  alkoxy  $C_{0-6}$ alkyl,
- (20) aryl C<sub>0-6</sub> alkoxy C<sub>0-6</sub>alkyl,
- (21) hydroxycarbonyl C<sub>0</sub>-6alkyl,
- (22) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (23) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (24) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (25) hydroxy C<sub>0</sub>-6alkyl,
- (26) cyano,
- (27) nitro,
- (28) perfluoroC<sub>1-4</sub>alkyl,
- (29) perfluoroC<sub>1-4</sub>alkoxy,
- (30) C<sub>1-6</sub> alkylcarbonyloxy,
- (31) aryl C<sub>0</sub>-6alkylcarbonyloxy,
- (32) C<sub>1-6</sub> alkylcarbonylamino,
- (33) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (34) C<sub>1-6</sub> alkylsulfonylamino,
- (35) aryl C<sub>0-6</sub>alkylsulfonylamino,
- (36) C<sub>1-6</sub> alkoxycarbonylamino,
- (37) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (38) C<sub>1-6</sub>alkylaminocarbonylamino,
- (39) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (42) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (44) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy, and
- (45) spiro-C3-8cycloalkyl;
- or, R<sup>4</sup> and R<sup>5</sup> together form an oxo group or =CH-R<sup>6</sup> or a spiro C 3-7 cycloalkyl ring substituted with R<sup>6</sup>;

R6 is selected from hydrogen and C<sub>1-4</sub> alkyl;

Case No.: 20880P

Page 16

 $R^7$  is selected from hydrogen, perfluoro  $C_{1-8}$  alkyl, and  $C_{1-8}$  alkyl, unsubstituted or substituted with one to three halogen atoms.

n is selected from: 0, 1, and 2;

and pharmaceutically acceptable salts thereof.

2. (Original) The method according to Claim 1, wherein:

"b" is a single bond, and "a" is a double bond;

X is selected from:

- (A) -C(O)-,
- (B) -C(O)-O-
- (C)  $-C(O)-N(R^7)$ -,and
- (D)  $-S(O)_{n}$ -;

R<sup>1</sup> is methyl;

R<sup>2</sup> is selected from:

- (A) aryl, substituted by one substituents selected from:
  - (1) fluoro,
  - (2) chloro,
  - (3) bromo,
  - (4) methyl,
  - (5) methoxy,
  - (6) ethoxy,
  - (7) hydroxy,
  - (8) trifluoromethyl,
  - (9) trifluoromethoxy, and
  - (10) acetyl;
- (B) C<sub>1-6</sub> alkyl, unsubstituted or substituted with one or two substituents independently selected from:

sciceta iio

- (1) fluoro,
- (2) chloro,
- (3) cyano,
- (4) methoxy,
- (5) hydroxy, and
- (6) trifluoromethyl;
- (C) trifluoromethyl;

PCT/US2004/013787 Case No.: 20880P

Page 17

(D)	phenyl-C <sub>1-6</sub> alkyl-, wherein phenyl is unsubstituted or substituted with one or two
	substituents independently selected from:

- (1) halogen,
- (2) methyl,
- (3)  $C_{1-2}$  alkoxy,
- (4) hydroxy,
- (5) nitro,
- (6) trifluoromethyl, and
- (7) trifluoromethoxy;.
- (E) C<sub>2-3</sub> alkenyl;
- (F) phenyl C2alkenyl, wherein phenyl is unsubstituted or substituted with a substituent selected from:
  - (1) halogen,
  - (2) methyl, and
  - (3) trifluoromethyl;
- (G) cycloheteroalkyl, either unsubstituted or substituted with one or two substituents selected from:
  - (1) fluoro,
  - (2) phenyl,
  - (3) C<sub>1-4</sub> alkyl,
  - (4)  $C_{1-3}$  alkoxy,
  - (5) hydroxy,
  - (6) trifluoromethyl,
  - (7) oxo, and
  - (8) spiro C<sub>3-8</sub> cycloalkyl;

provided that any heteroatom substituent is bonded to a carbon atom in the cycloheteroalkyl ring; R<sup>3</sup> is hydrogen;

R<sup>4</sup> and R<sup>5</sup> are each hydrogen;

R6 is hydrogen;

R<sup>7</sup> is hydrogen,

n is 2;

and pharmaceutically acceptable salts thereof.

Case No.: 20880P

Page 18

- 3. (Original) The method according to Claim 1 wherein the androgen receptor is antagonized in the prostate of a male patient or in the uterus of a female patient and agonized in bone or muscle tissue.
- 4. (Original) The method according to Claim 1 wherein modulating the androgen receptor in a tissue selective manner comprises agonizing the androgen receptor.
- 5. (Original) A method of treating a condition which is caused by androgen deficiency or which can be ameliorated by androgen administration selected from: osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, HIV-wasting, cancer cachexia, bone fracture, bone damage following bone reconstructive surgery, muscular dystrophies, sarcopenia, frailty, aging skin, male hypogonadism, post-menopausal symptoms in women, female sexual dysfunction, premature ovarian failure, autoimmune disease, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, arthritis and joint repair, in a patient in need of such treatment, comprising modulating the androgen receptor in said patient according to the method of Claim 1.
- 6. (Original) The method according to Claim 5 wherein the condition is osteoporosis.
  - 7. (**Original**) The method according to Claim 6 wherein:

"b" is a single bond, and "a" is a double bond;

X is selected from:

- (A) -C(O)-,
- (B) -C(O)-O-,
- (C)  $-C(O)-N(R^7)$ -,and
- (D)  $-S(O)_{n}$ -;

R<sup>1</sup> is methyl;

R<sup>2</sup> is selected from:

- (A) aryl, substituted by one substituents selected from:
  - (1) fluoro,
  - (2) chloro,
  - (3) bromo,
  - (4) methyl,
  - (5) methoxy,

Case No.: 20880P

Dogo	10	
Page	19	

(6)	ethoxy,
-----	---------

- (7) hydroxy,
- (8) trifluoromethyl,
- (9) trifluoromethoxy, and
- (10) acetyl;
- (B) C<sub>1-6</sub> alkyl, unsubstituted or substituted with one or two substituents independently selected from:
  - (1) fluoro,
  - (2) chloro,
  - (3) cyano,
  - (4) methoxy,
  - (5) hydroxy, and
  - (6) trifluoromethyl;
- (C) trifluoromethyl;
- (D) phenyl-C<sub>1-6</sub> alkyl-, wherein phenyl is unsubstituted or substituted with one or two substituents independently selected from:
  - (1) halogen,
  - (2) methyl,
  - (3)  $C_{1-2}$  alkoxy,
  - (4) hydroxy,
  - (5) nitro,
  - (6) trifluoromethyl, and
  - (7) trifluoromethoxy;.
- (E) C<sub>2-3</sub> alkenyl;
- (F) phenyl C2alkenyl, wherein phenyl is unsubstituted or substituted with a substituent selected from:
  - (1) halogen,
  - (2) methyl, and
  - (3) trifluoromethyl;
- (G) cycloheteroalkyl, either unsubstituted or substituted with one or two substituents selected from:
  - (1) fluoro,
  - (2) phenyl,
  - (3)  $C_{1-4}$  alkyl,

Case No.: 20880P Page 20

- (4)  $C_{1-3}$  alkoxy,
- (5) hydroxy,
- (6) trifluoromethyl,
- (7) oxo, and
- (8) spiro C<sub>3-8</sub> cycloalkyl;

provided that any heteroatom substituent is bonded to a carbon atom in the cycloheteroalkyl ring;

R<sup>3</sup> is hydrogen;

R<sup>4</sup> and R<sup>5</sup> are each hydrogen;

R6 is hydrogen;

R<sup>7</sup> is hydrogen,

n is 2;

and pharmaceutically acceptable salts thereof.

- 8. **(Presently amended)** The method according to Claim 7 wherein the compound is selected from:
- (1) 4-methyl-17 $\beta$ -(2-trifluoromethylbenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (2) 4-methyl-17 $\beta$ -(3-trifluoromethylbenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (3) 4-methyl-17 $\beta$ -(2-methoxybenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (4) 4-methyl-17 $\beta$ -(3-methoxybenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (5) 4-methyl-17 $\beta$ -(4-methoxybenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (6) 4-methyl-17 $\beta$ -(4-cyanobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (7) 4-methyl-17 $\beta$ -(2-chloro-pyrid-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (8) 4-methyl-17 $\beta$ -(pyrid-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (9) 4-methyl-17 $\beta$ -(pyrid-4-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (10) 4-methyl- $17\beta$ -(4-(carboxymethyl)benzamido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (11) 4-methyl-17 $\beta$ --(pyrid-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (12) 4-methyl-17 $\beta$ -(2-fluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (13) 4-methyl-17 $\beta$ -(3-fluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (14) 4-methyl-17 $\beta$ -(4-fluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (15) 4-methyl-17 $\beta$ -(2,4-difluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (16) 4-methyl-17 $\beta$ -(4-chlorobutyramido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (17) 4-methyl-17 $\beta$ -(4-bromobutyramido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (18) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-bromoethyl ester;$
- (19) 4-methyl-17 $\beta$ -(2-methylpropamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;

Case No.: 20880P

- (20) 4-methyl-17 $\beta$ -(2-methoxyacetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (21) 4-methyl-17 $\beta$ -(cyclopropamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (22) 4-methyl-17 $\beta$ -(acetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (23) 4-methyl- $17\beta$ -(trifluoroacetamido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (24) 4-methyl-17 $\beta$ -(3,3,3-trifluoropropionamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (25) 4-methyl-17 $\beta$ -(2-cyanoacetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (26) 4-methyl-17 $\beta$ -(2-methyl-2-hydroxypropamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (27) 4-methyl-17 $\beta$ -(thiazo-4-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (28) 4-methyl-17 $\beta$ -(pyrimid-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (29) 4-methyl-17 $\beta$ -(pyrimid-4-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (30) 4-methyl-17 $\beta$ -(oxazo-5-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (31) 4-methyl-17β-(1-methyl-imidazo-2-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (32) 4-methyl-17 $\beta$ -(furan-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (33) 4-methyl-17 $\beta$ -(furan-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (34) 4-methyl-17 $\beta$ -(thiophene-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (35) 4-methyl-17 $\beta$ -(thiophene-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (36) 4-methyl-17 $\beta$ -(pyridazin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (37) 4-methyl-17 $\beta$ -(5-methyl-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (38) 4-methyl-17β-(5-chloro-pyridin-2-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (39) 4-methyl-17 $\beta$ -(quinoline-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (40) 4-methyl-17 $\beta$ -(quinoline-8-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (41) 4-methyl-17 $\beta$ -(isoquinoline-8-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (42) 4-methyl-17 $\beta$ -(2-chlorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (43) 4-methyl-17 $\beta$ -(3-chlorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (44) 4-methyl-17 $\beta$ -(4-chlorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (45) 4-methyl-17 $\beta$ -(formamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (46) 4-methyl-17 $\beta$ -[(2-trifluoromethylphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (47) 4-methyl-17 $\beta$ -[(4-trifluoromethylphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (48) 4-methyl-17 $\beta$ -[(2-chlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (49) 4-methyl-17 $\beta$ -[(3-chlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (50) 4-methyl-17 $\beta$ -[(4-chlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (51) 4-methyl-17 $\beta$ -[(2,4-dichlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (52) 4-methyl-17 $\beta$ -[(3-fluorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (53) 4-methyl-17 $\beta$ -[(4-fluorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;

Case No.: 20880P

- Page 22
- (54) 4-methyl-17 $\beta$ -[(2-methoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (55) 4-methyl-17 $\beta$ -[(3-methoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (56) 4-methyl-17 $\beta$ -[(2,5-dimethoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (57) 4-methyl- $17\beta$ -[(3,5-difluorophenyl)acetamido]-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (58) 4-methyl-17 $\beta$ -[(3-nitrophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (59) 4-methyl-17 $\beta$ -(tetrahydrofuran-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (60) 4-methyl-17 $\beta$ -(tetrahydrofuran-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (61) 4-methyl-17 $\beta$ -(4-ethyl-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (62) 4-methyl-17β–(3-methyl-pyridin-2-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (63) 4-methyl-17 $\beta$ -(3-bromo-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (64) 4-methyl-17 $\beta$ -(4-bromo-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (65) 4-methyl-17 $\beta$ -[(2-phenylcyclopropyl)amido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (66) 4-methyl- $17\beta$ -[(2-fluorophenyl)acetamido]-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (67) 4-methyl-17 $\beta$ -[(pyrid-2-yl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (68) 4-methyl-17 $\beta$ -[(pyrid-3-yl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (69) 4-methyl-17β-[(4-methoxyphenyl)acetamido]-4-aza-5α-androst-1-ene-3-one;
- (70) 4-methyl-17 $\beta$ -[3-(2-fluorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (71) 4-methyl-17 $\beta$ -[3-(4-fluorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (72) 4-methyl-17 $\beta$ -[3-(4-rifluoromethylphenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3- one;
- (73) 4-methyl-17 $\beta$ -[3-(2-chlorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (74) 4-methyl-17 $\beta$ -[3-(3-chlorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (75) 4-methyl-17 $\beta$ -[3-(4-chlorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (76) 4-methyl-17β-[2-trifluoromethylcinnamido]-4-aza-5α-androst-1-ene-3-one;
- (77) 4-methyl-17 $\beta$ -[2-chlorocinnamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (78) 4-methyl-17 $\beta$ -[2-fluorocinnamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (79) 4-methyl-17β-[4-(2,5-dichlorophenyl)butanamido]-4-aza-5α-androst-1-ene-3-one;
- (80) 4-methyl-17β-[4-(2-nitrophenyl)butanamido]-4-aza-5α-androst-1-ene-3-one;
- (81) 4-methyl-17 $\beta$ -[4-(3,4-dimethoxyphenyl)butanamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (82) 4-methyl-17 $\beta$ -[propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (83) 4-methyl-17 $\beta$ -[butyramido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (84) 4-methyl-17 $\beta$ -[(2-methyl)cyclopropamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (85) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -phenyl ester;
- (86) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-chlorophenyl ester;$
- (87) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-nitrophenyl ester;$

Case No.: 20880P Page 23

- (88) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-methylphenyl ester;$
- (89) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-bromophenyl ester;$
- (90) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-fluorophenyl ester;$
- (91) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-methoxophenyl ester;$
- (92) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-nitrophenyl ester;$
- (93) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-naphthyl ester;$
- (94) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-trifluoromethylphenyl ester;$
- (95) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -ethyl ester;
- (96) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-benzyl ester;$
- (97) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2,2,2-trifluoroethyl ester;$
- (98) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-methoxyethyl ester;$
- (99) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-(2,2-dimethylpropy)$  ester;
- (100) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-fluoroethyl ester;$
- (101) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -allyl ester;
- (102) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -methyl ester;
- (103) Carbamic acid,  $[(5\alpha,17\beta)-3-\infty-4-methyl-azaandrost-1-ene-17-yl]-1-propynoic ester;$
- (104) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-(2-methyl-2-butyl)$  ester;
- (105) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-(trifluoromethyl)phenyl ester;$
- (106) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-(trifluoromethyl)phenyl ester;$
- (107) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-fluorophenyl ester;$
- (108) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-fluorophenyl ester;$
- (109) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-(2-hydroxy-1-ethyl)$  ester;
- (110) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-methoxyphenyl ester;$
- (111) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-methoxyphenyl ester;$
- (112) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-ethoxyphenyl ester;$
- (113) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-ethoxyphenyl ester;$
- (114) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-ethoxyphenyl ester;$

Case No.: 20880P Page 24

- (115) Carbamic acid, [(5α,17β)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-chlorophenyl ester;
- (116) Carbamic acid, [(5α,17β)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-chlorophenyl ester;
- (117) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-(trifluoromethoxy)phenyl ester;$
- (118) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-$  (trifluoromethoxy)phenyl ester;
- (119) Carbamic acid, [(5α,17β)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-propyl ester;
- (120) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-propyl ester;$
- (121) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-butyl ester;$
- (122) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-hexyl ester;$
- (123) 4-methyl-17β-(phenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (124) 4-methyl-17 $\beta$ -(2-trifluoromethylphenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (125) 4-methyl-17β-(3-trifluoromethylphenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (126) 4-methyl-17 $\beta$ -(2-chlorophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (127) 4-methyl-17 $\beta$ -(3-chlorophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (128) 4-methyl- $17\beta$ -(2-trifluoromethoxyphenylsulfonamido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (129) 4-methyl-17 $\beta$ -(2-cyanophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (130) 4-methyl-17β-(4-methoxyphenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (131) 4-methyl-17β-(3-bromo-5--methoxyphenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (132) 4-methyl-17 $\beta$ -(8-quinolylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (133) 4-methyl-17 $\beta$ -(3-cyanophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (134) 4-methyl-17β-(4-chlorophenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (135) 4-methyl-17 $\beta$ -[(2-methylsufonyl)phenyl]sulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (136) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- phenyl urea;
- (137) N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2-trifluoromethyl)phenyl urea;
- (138) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (3-trifluoromethyl)phenyl urea;
- (139) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- 3-chlorophenyl urea;
- (140) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (4-chloro-2-trifluoromethylphenyl) urea;
- (141) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- 3-acetylphenyl urea;
- (142) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (5-chloro-2-trifluoromethylphenyl) urea;
- (143) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2,4-[bistrifluoromethyl]phenyl) urea;

Case No.: 20880P

- (144) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (3,4-difluorophenyl) urea;
- (145) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2,3-dichlorophenyl) urea;
- (146) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2,4-dichlorophenyl) urea;
- (147) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (3,4-dichlorophenyl) urea;
- (148)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-2-chlorophenyl) urea;$
- (149) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2-chloro-5-trifluoromethylphenyl) urea;
- (150) N- $[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (4-chloro-3-trifluoromethylphenyl) urea;$
- (151) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-(4-trifluoromethyl)phenyl urea;
- (152)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-(2,3-dimethylphenyl) urea;$
- (153)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-methyl urea;$
- (154)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-ethyl urea;$
- (155)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-dimethyl urea;$
- (156)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-diethyl urea;$
- (157) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl] urea;
  - (147) N-[(5I,178) 4-methyl-3-oxo 4-azaandrost-1-en-17-yl] N'- (3,4-dichlorophenyl) urea;
  - (148) N [(51,178) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' 2 ehlorophenyl) urea;
  - (149) N [(5I,178) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' (2 ehloro 5 trifluoromethylphenyl) urea;
  - (150) N-[(5I,170) 4-methyl-3-oxo 4-azaandrost-1-en-17-yl] N'- (4-ehloro-3-trifluoromethylphenyl) urea;
  - (151) N-[(5I,178) 4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N' (4-trifluoromethyl)phenyl-urea;
  - (152) N [(5I,178) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' (2,3 dimethylpheny) urea;
  - (153) N-[(5I,170) 4 methyl-3 oxo 4-azaandrost-1-en-17-yl] N' methyl urea;
  - (154) N [(5I,178) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' ethyl urea;
  - (155) N [(51,178) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' dimethyl urea;
  - (156) N [(5I,170) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' diethyl urea;
  - (157) N-[(51,178) 4-methyl-3-oxo 4-azaandrost-1-en-17-yl] urea;

Case No.: 20880P

Page 26

and pharmaceutically acceptable salts thereof.

# 9. (**Presently amended**) The method according to Claim 1 wherein the compound is selected from:

- (1) 4-methyl- $17\beta$ -(2-trifluoromethylbenzamido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (2) 4-methyl-17 $\beta$ -(3-trifluoromethylbenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (3) 4-methyl-17 $\beta$ -(2-methoxybenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (4) 4-methyl-17 $\beta$ -(3-methoxybenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (5) 4-methyl-17 $\beta$ -(4-methoxybenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (6) 4-methyl-17 $\beta$ -(4-cyanobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (7) 4-methyl-17 $\beta$ -(2-chloro-pyrid-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (8) 4-methyl-17 $\beta$ -(pyrid-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (9) 4-methyl-17 $\beta$ -(pyrid-4-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (10) 4-methyl-17 $\beta$ -(4-(carboxymethyl)benzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (11) 4-methyl-17 $\beta$ -(pyrid-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (12) 4-methyl-17 $\beta$ -(2-fluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (13) 4-methyl-17 $\beta$ -(3-fluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (14) 4-methyl-17 $\beta$ -(4-fluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (15) 4-methyl-17 $\beta$ -(2,4-difluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (16) 4-methyl-17 $\beta$ -(4-chlorobutyramido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (17) 4-methyl-17 $\beta$ -(4-bromobutyramido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (18) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-bromoethyl ester;$
- (19) 4-methyl-17 $\beta$ -(2-methylpropamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (20) 4-methyl-17 $\beta$ -(2-methoxyacetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (21) 4-methyl-17 $\beta$ -(cyclopropamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (22) 4-methyl-17 $\beta$ -(acetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (23) 4-methyl-17 $\beta$ -(trifluoroacetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (24) 4-methyl- $17\beta$ -(3,3,3-trifluoropropionamido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (25) 4-methyl- $17\beta$ -(2-cyanoacetamido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (26) 4-methyl- $17\beta$ -(2-methyl-2-hydroxypropamido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (27) 4-methyl-17 $\beta$ -(thiazo-4-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (28) 4-methyl- $17\beta$ -(pyrimid-2-yl-amido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (29) 4-methyl-17 $\beta$ -(pyrimid-4-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (30) 4-methyl-17 $\beta$ -(oxazo-5-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;

- (31) 4-methyl-17 $\beta$ -(1-methyl-imidazo-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (32) 4-methyl-17 $\beta$ -(furan-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (33) 4-methyl-17 $\beta$ -(furan-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (34) 4-methyl-17 $\beta$ -(thiophene-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (35) 4-methyl-17 $\beta$ -(thiophene-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (36) 4-methyl-17 $\beta$ -(pyridazin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (37) 4-methyl-17 $\beta$ -(5-methyl-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (38) 4-methyl-17 $\beta$ -(5-chloro-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (39) 4-methyl-17 $\beta$ -(quinoline-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (40) 4-methyl-17 $\beta$ -(quinoline-8-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (41) 4-methyl-17β-(isoquinoline-8-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (42) 4-methyl-17 $\beta$ -(2-chlorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (43) 4-methyl-17 $\beta$ -(3-chlorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (44) 4-methyl-17 $\beta$ -(4-chlorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (45) 4-methyl-17 $\beta$ -(formamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (46) 4-methyl- $17\beta$ -[(2-trifluoromethylphenyl)acetamido]-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (47) 4-methyl-17β-[(4-trifluoromethylphenyl)acetamido]-4-aza-5α-androst-1-ene-3-one;
- (48) 4-methyl-17 $\beta$ -[(2-chlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (49) 4-methyl-17 $\beta$ -[(3-chlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (50) 4-methyl- $17\beta$ -[(4-chlorophenyl)acetamido]-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (51) 4-methyl-17 $\beta$ -[(2,4-dichlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (52) 4-methyl-17 $\beta$ -[(3-fluorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (53) 4-methyl-17 $\beta$ -[(4-fluorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (54) 4-methyl-17 $\beta$ -[(2-methoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (55) 4-methyl-17 $\beta$ -[(3-methoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (56) 4-methyl-17 $\beta$ -[(2,5-dimethoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (57) 4-methyl-17 $\beta$ -[(3,5-difluorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (58) 4-methyl-17 $\beta$ -[(3-nitrophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (59) 4-methyl-17β-(tetrahydrofuran-2-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (60) 4-methyl-17β-(tetrahydrofuran-3-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (61) 4-methyl-17 $\beta$ -(4-ethyl-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (62) 4-methyl-17 $\beta$ -(3-methyl-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (63) 4-methyl-17β–(3-bromo-pyridin-2-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (64) 4-methyl-17 $\beta$ -(4-bromo-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;

Case No.: 20880P

- (65) 4-methyl-17 $\beta$ -[(2-phenylcyclopropyl)amido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (66) 4-methyl-17 $\beta$ -[(2-fluorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (67) 4-methyl-17 $\beta$ -[(pyrid-2-yl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (68) 4-methyl-17 $\beta$ -[(pyrid-3-yl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (69) 4-methyl-17 $\beta$ -[(4-methoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (70) 4-methyl- $17\beta$ -[3-(2-fluorophenyl)propionamido]-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (71) 4-methyl-17 $\beta$ -[3-(4-fluorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (72) 4-methyl- $17\beta$ -[3-(4-rifluoromethylphenyl)propionamido]-4-aza- $5\alpha$ -androst-1-ene-3- one;
- (73) 4-methyl-17 $\beta$ -[3-(2-chlorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (74) 4-methyl-17β-[3-(3-chlorophenyl)propionamido]-4-aza-5α-androst-1-ene-3-one;
- (75) 4-methyl-17 $\beta$ -[3-(4-chlorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (76) 4-methyl-17β-[2-trifluoromethylcinnamido]-4-aza-5α-androst-1-ene-3-one;
- (77) 4-methyl-17β-[2-chlorocinnamido]-4-aza-5α-androst-1-ene-3-one;
- (78) 4-methyl-17 $\beta$ -[2-fluorocinnamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (79) 4-methyl-17 $\beta$ -[4-(2,5-dichlorophenyl)butanamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (80) 4-methyl-17 $\beta$ -[4-(2-nitrophenyl)butanamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (81) 4-methyl-17 $\beta$ -[4-(3,4-dimethoxyphenyl)butanamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (82) 4-methyl-17 $\beta$ -[propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (83) 4-methyl-17 $\beta$ -[butyramido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (84) 4-methyl-17 $\beta$ -[(2-methyl)cyclopropamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (85) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -phenyl ester;
- (86) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-chlorophenyl ester;$
- (87) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-nitrophenyl ester;$
- (88) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-methylphenyl ester;$
- (89) Carbamic acid, [(5α,17β)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-bromophenyl ester;
- (90) Carbamic acid,  $[(5\alpha, 17\beta)-3-\infty-4-methyl-azaandrost-1-ene-17-yl]-4-fluorophenyl ester;$
- (91) Carbamic acid, [(5α,17β)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-methoxophenyl ester;
- (92) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-nitrophenyl ester;$
- (93) Carbamic acid,  $[(5\alpha,17\beta)-3-\infty-4-methyl-azaandrost-1-ene-17-yl]-3-naphthyl ester;$
- (94) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-trifluoromethylphenyl ester;$
- (95) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -ethyl ester;
- (96) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -benzyl ester;

- (97) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2,2,2-trifluoroethyl ester;$
- (98) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-methoxyethyl ester;$
- (99) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-(2,2-dimethylpropy)$  ester;
- (100) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-fluoroethyl ester;$
- (101) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-allyl ester;$
- (102) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -methyl ester;
- (103) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-propynoic ester;$
- (104) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-(2-methyl-2-butyl)$  ester;
- (105) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-(trifluoromethyl)phenyl ester;$
- (106) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-(trifluoromethyl)phenyl ester;$
- (107) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-fluorophenyl ester;$
- (108) Carbamic acid, [(5α,17β)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-fluorophenyl ester;
- (109) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-(2-hydroxy-1-ethyl)$  ester;
- (110) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-methoxyphenyl ester;$
- (111) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-methoxyphenyl ester;$
- (112) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-ethoxyphenyl ester;$
- (113) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-ethoxyphenyl ester;$
- (114) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-ethoxyphenyl ester;$
- (115) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-chlorophenyl ester;$
- (116) Carbamic acid, [(5α,17β)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-chlorophenyl ester;
- (117) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-(trifluoromethoxy)phenyl ester;$
- (118) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-$  (trifluoromethoxy)phenyl ester;
- (119) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-propyl ester;$
- (120) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-propyl ester;$
- (121) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-butyl ester;$
- (122) Carbamic acid,  $[(5\alpha, 17\beta)-3-\infty-4-methyl-azaandrost-1-ene-17-yl]-1-hexyl ester;$

Case No.: 20880P Page 30

- (123) 4-methyl-17β-(phenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (124) 4-methyl-17β-(2-trifluoromethylphenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (125) 4-methyl-17 $\beta$ -(3-trifluoromethylphenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (126) 4-methyl-17 $\beta$ -(2-chlorophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (127) 4-methyl-17 $\beta$ -(3-chlorophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (128) 4-methyl-17 $\beta$ -(2-trifluoromethoxyphenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (129) 4-methyl-17 $\beta$ -(2-cyanophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (130) 4-methyl-17 $\beta$ -(4-methoxyphenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (131) 4-methyl-17 $\beta$ -(3-bromo-5--methoxyphenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (132) 4-methyl-17 $\beta$ -(8-quinolylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (133) 4-methyl-17β-(3-cyanophenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (134) 4-methyl-17 $\beta$ -(4-chlorophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (135) 4-methyl-17 $\beta$ -[(2-methylsufonyl)phenyl]sulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (136) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- phenyl urea;
- (137) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2-trifluoromethyl)phenyl urea;
- (138) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (3-trifluoromethyl)phenyl urea;
- (139) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- 3-chlorophenyl urea;
- (140) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (4-chloro-2-trifluoromethylphenyl) urea;
- (141) N-[ $(5\alpha, 17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- 3-acetylphenyl urea;
- (142) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (5-chloro-2-trifluoromethylphenyl) urea;
- (143) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2,4-[bistrifluoromethyl]phenyl) urea;
- (144) N- $[(5\alpha, 17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (3,4-difluorophenyl) urea;
- (145) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2,3-dichlorophenyl) urea;
- (146) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2,4-dichlorophenyl) urea;
- (147)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-(3,4-dichlorophenyl) urea;$
- (148)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-2-chlorophenyl)$  urea;
- (149) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2-chloro-5-trifluoromethylphenyl) urea;
- (150) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (4-chloro-3-trifluoromethylphenyl) urea;

Case No.: 20880P

- (151) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-(4-trifluoromethyl)phenyl urea;
- (152)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-(2,3-dimethylphenyl) urea;$
- (153)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-methyl urea;$
- (154)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-ethyl urea;$
- (155)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-dimethyl urea;$
- (156)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-diethyl urea;$
- (157) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl] urea;
  - (147) N [(5I,178) 4-methyl 3 oxo 4-azaandrost 1 en 17 yl] N' (3,4-dichlorophenyl) urea;
  - (148) N [(5I,170) 4 methyl-3-oxo-4-azaandrost-1-en-17 yl] N' 2 chlorophenyl) urea;
  - (149) N-[(5I,178) 4 methyl-3-oxo-4-azaandrost-1-en-17-yl]-N' (2 chloro-5-trifluoromethylphenyl) urea;
  - (150) N-[(5I,170) 4 methyl-3-oxo-4-azaandrost-1-en-17-yl]-N' (4-chloro-3-trifluoromethylphenyl) urea;
  - (151) N-[(5I,170) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' (4-trifluoromethyl)phenyl urea;
  - (152) N [(5I,170) 4-methyl 3 oxo 4 azaandrost 1 en 17-yl]-N'-(2,3-dimethylpheny) urea;
  - (153) N [(5I,170) 4 methyl 3 oxo 4 azaandrost 1 en 17-yl] N' methyl urea;
  - (154) N [(5I,178) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' ethyl urea;
  - (155) N-[(5I,170) 4-methyl-3-oxo-4-azaandrost 1 en 17 yl] N'-dimethyl-urea;
  - (156) N-[(5I,170) 4 methyl-3-oxo 4 azaandrost-1-en-17 yl] N' diethyl urea;
- (157) N [(5I,170) 4 methyl 3 oxo 4 azaandrost 1 en 17-yl] urea; and a pharmaceutically acceptable salts thereof.
- 10. (**Original**) The method according to Claim 6, additionally comprising the administration of a bone-strengthening agent selected from:
  - (a) estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative,
  - (b) a bisphosphonate,
  - (c) an antiestrogen or a selective estrogen receptor modulator,
  - (d) an osteoclast integrin inhibitor,
  - (e) a cathepsin K inhibitor,

Case No.: 20880P

Page 32

- (f) an HMG-CoA reductase inhibitor,
- (g) an osteoclast vacuolar ATPase inhibitor,
- (h) an antagonist of VEGF binding to osteoclast receptors,
- (i) a peroxisome proliferator-activated receptor γ,
- (j) calcitonin,
- (k) a calcium receptor antagonist,
- (1) parathyroid hormone,
- (m) a growth hormone secretagogue,
- (n) human growth hormone,
- (o) insulin-like growth factor,
- (p) a P-38 protein kinase inhibitor,
- (q) bone morphogenic protein,
- (r) an inhibitor of BMP antagonism,
- (s) a prostaglandin derivative,
- (t) vitamin D or vitamin D derivative,
- (u) vitamin K or vitamin K derivative,
- (v) ipriflavone,
- (w) fluoride salts, and
- (x) dietary calcium supplement.

#### 11. (Original) The method according to Claim 10, wherein:

- (a) the estrogen or estrogen derivative, alone or in combination with a progestin or progestin derivative is selected from: conjugated estrogen, equine estrogen, 17β-estradiol, estrone, 17β-ethynyl estradiol, alone or in combination with an agent selected from norethindrone and medroxyprogesterone acetate;
- (b) the bisphosphonate is selected from:
  - (1) 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid,
  - (2) N-methyl-4-amino-hydroxybutylidene-1,1-bisphosphonic acid,
  - (3) 4-(N,N-dimethylamino-1-hydroxybutylidene-1,1-bisphosphonic acid,
  - (4) 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid,
  - (5) 3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1- bisphosphonic acid,
  - (6) 1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid,
  - (7) 1-hydroxy-2-(3-pyridyl)ethylidene-1,1-bisphosphonic acid,
  - (8) 4-(hydroxymethylene-1,1-bisphosphonic acid)piperidine,

Case No.: 20880P Page 33

- (9) (1-hydroxyethylidene)-bisphosphonate,
- (10) (dichloromethylene)-bisphosphonate,
- (11) [1-hydroxy-2-imidazopyridin-(1,2-a)-3-ylethylidene] bisphosphonate,
- (12) (6-amino-1-hydroxyhexylidene)bisphosphonate, and
- (13) [1-hydroxy-2-(1H-imidazole-1-yl)ethylidene]bisphosphonate;
- (c) the antiestrogen or selective estrogen receptor modulator is selected from: raloxifene, clomiphene, zuclomiphene, enclomiphene, nafoxidene, CI-680, CI-628, CN-55,945-27, Mer-25, U-11, 555A, U-100A tamoxifen, lasofoxifene, toremifene, azorxifene, EM-800, EM-652, TSE 424, droloxifene, idoxifene, and levormeloxifene;
- (d) the osteoclast integrin inhibitor is selected from an alphavbeta3 inhibitor or mixed alphavbeta3 and alphavbeta5 inhibitor;
- (e) the HMG-CoA reductase inhibitor is selected from lovastatin, simvastatin, dihydroxyopen acid simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and nisvastatin;
- (f) calcitonin is salmon calcitonin administered as a nasal spray;
- (g) bone morphogenic protein is selected from BMP 2, BMP 3, BMP 5, BMP 6, BMP 7, TGF beta, and GDF5;
- (h) insulin-like growth factor is selected from IGF I and IGF II alone or in combination with IGF binding protein 3;
- (i) the prostaglandin derivative is selected from agonists of prostaglandin receptor EP1, EP2, EP4, FP, and IP;
- (j) the fibroblast growth factor is selected from aFGF and bFGF;
- (k) parathyroid hormone or parathyroid hormone analog is selected from parathyroid hormone subcutaneous injection, human PTH, 1-84, 1-34 and other partial sequences, native or with substitutions;
- (l) vitamin D or vitamin D derivative is selected from: natural vitamin D, 25-OH-vitamin D3, 1α,25(OH)<sub>2</sub> vitamin D3, 1α-OH-vitamin D3, 1α-OH-vitamin D2, dihydrotachysterol, 26,27-F6-1α,25(OH)<sub>2</sub> vitamin D3, 19-nor-1α,25(OH)<sub>2</sub> vitamin D3, 22-oxacalcitriol, calcipotriol, 1α,25(OH)<sub>2</sub>-16-ene-23-yne-vitamin D3 (Ro 23-7553), EB1089, 20-epi-1α,25(OH)<sub>2</sub> vitamin D3, KH1060, ED71, 1α,24(S)-(OH)<sub>2</sub> vitamin D3, and 1α,24(R)-(OH)<sub>2</sub> vitamin D3;
- (m) the dietary calcium supplement is selected from calcium carbonate, calcium citrate, and natural calcium salts;

Case No.: 20880P

Page 34

(n) the fluoride salts are selected from: sodium fluoride and monosodium fluorophosphate (MFP);

and pharmaceutically acceptable salts thereof.

- 12. (Original) The method according to Claim 11, additionally comprising the administration of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt, trihydrate.
- 13. (**Original**) The method according to Claim 1, additionally comprising the administration of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt, trihydrate.
  - 14. (Original) A compound of structural formula I:

wherein:

"b" is a single bond, and "a" is a double bond;

X is selected from:

- (A) -C(O)-,
- (B) -C(O)-O-,
- (C)  $-C(O)-N(R^7)$ -,and
- (D)  $-S(O)_{n}$ -;

R<sup>1</sup> is methyl;

R2 is selected from:

- (A) aryl, substituted by one substituents selected from:
  - (1) fluoro,
  - (2) chloro,

Case No.: 20880P Page 35

(3)	bromo,
(2)	UI OIIIO,

- (4) methyl,
- (5) methoxy,
- (6) ethoxy,
- (7) hydroxy,
- (8) trifluoromethyl,
- (9) trifluoromethoxy, and
- (10) acetyl;.
- (B) C<sub>1-6</sub> alkyl, unsubstituted or substituted with one or two substituents independently selected from:
  - (1) fluoro,
  - (2) chloro,
  - (3) cyano,
  - (4) methoxy,
  - (5) hydroxy, and
  - (6) trifluoromethyl;
- (C) trifluoromethyl;
- (D) phenyl-C<sub>1-6</sub> alkyl-, wherein phenyl is unsubstituted or substituted with one or two substituents independently selected from:
  - (1) halogen,
  - (2) methyl,
  - (3)  $C_{1-2}$  alkoxy,
  - (4) hydroxy,
  - (5) nitro,
  - (6) trifluoromethyl, and
  - (7) trifluoromethoxy;.
- (E) C<sub>2-3</sub> alkenyl;
- (F) phenyl C2alkenyl, wherein phenyl is unsubstituted or substituted with a substituent selected from:
  - (1) halogen,
  - (2) methyl, and
  - (3) trifluoromethyl.
- (G) cycloheteroalkyl, either unsubstituted or substituted with one or two substituents selected from:

Case No.: 20880P

Page 36

- (1) fluoro,
- (2) phenyl,
- (3) C<sub>1-4</sub> alkyl,
- (4)  $C_{1-3}$  alkoxy,
- (5) hydroxy,
- (6) trifluoromethyl,
- (7) oxo, and
- (8) spiro C<sub>3-8</sub> cycloalkyl;

provided that any heteroatom substituent is bonded to a carbon atom in the cycloheteroalkyl ring;

R<sup>3</sup> is hydrogen;

R4 and R5 are each hydrogen;

R6 is hydrogen;

R<sup>7</sup> is hydrogen,

n is 2;

and pharmaceutically acceptable salts thereof.

#### 15. (Presently Amended) A compound selected from:

- (1) 4-methyl-17 $\beta$ -(2-trifluoromethylbenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (2) 4-methyl-17 $\beta$ -(3-trifluoromethylbenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (3) 4-methyl-17 $\beta$ -(2-methoxybenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (4) 4-methyl-17 $\beta$ -(3-methoxybenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (5) 4-methyl-17 $\beta$ -(4-methoxybenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (6) 4-methyl-17 $\beta$ -(4-cyanobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (7) 4-methyl- $17\beta$ -(2-chloro-pyrid-3-yl-amido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (8) 4-methyl-17 $\beta$ -(pyrid-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (9) 4-methyl-17 $\beta$ -(pyrid-4-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (10) 4-methyl- $17\beta$ -(4-(carboxymethyl)benzamido)-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (11) 4-methyl-17 $\beta$ -(pyrid-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (12) 4-methyl-17 $\beta$ -(2-fluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (13) 4-methyl-17 $\beta$ -(3-fluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (14) 4-methyl-17 $\beta$ -(4-fluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (15) 4-methyl-17 $\beta$ -(2,4-difluorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (16) 4-methyl-17 $\beta$ -(4-chlorobutyramido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (17) 4-methyl-17 $\beta$ -(4-bromobutyramido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;

- (18) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-y]-2-bromoethyl ester;$
- (19) 4-methyl-17 $\beta$ -(2-methylpropamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (20) 4-methyl-17 $\beta$ -(2-methox yacetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (21) 4-methyl-17 $\beta$ -(cyclopropamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (22) 4-methyl-17 $\beta$ -(acetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (23) 4-methyl-17 $\beta$ -(trifluoroacetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (24) 4-methyl-17 $\beta$ -(3,3,3-trifluoropropionamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (25) 4-methyl-17 $\beta$ -(2-cyanoacetamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (26) 4-methyl-17 $\beta$ -(2-methyl-2-hydroxypropamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (27) 4-methyl-17 $\beta$ -(thiazo-4-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (28) 4-methyl-17 $\beta$ -(pyrimid-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (29) 4-methyl-17 $\beta$ -(pyrimid-4-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (30) 4-methyl-17 $\beta$ -(oxazo-5-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (31) 4-methyl-17β–(1-methyl-imidazo-2-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (32) 4-methyl-17 $\beta$ -(furan-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (33) 4-methyl-17 $\beta$ -(furan-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (34) 4-methyl-17 $\beta$ -(thiophene-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (35) 4-methyl-17 $\beta$ -(thiophene-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (36) 4-methyl-17 $\beta$ -(pyridazin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (37) 4-methyl-17β-(5-methyl-pyridin-2-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (38) 4-methyl-17 $\beta$ -(5-chloro-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (39) 4-methyl-17 $\beta$ -(quinoline-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (40) 4-methyl-17 $\beta$ -(quinoline-8-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (41) 4-methyl-17β-(isoquinoline-8-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (42) 4-methyl-17 $\beta$ -(2-chlorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (43) 4-methyl-17 $\beta$ -(3-chlorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (44) 4-methyl-17 $\beta$ -(4-chlorobenzamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (45) 4-methyl-17 $\beta$ -(formamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (46) 4-methyl-17 $\beta$ -[(2-trifluoromethylphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (47) 4-methyl-17 $\beta$ -[(4-trifluoromethylphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (48) 4-methyl-17 $\beta$ -[(2-chlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (49) 4-methyl-17 $\beta$ -[(3-chlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (50) 4-methyl-17 $\beta$ -[(4-chlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (51) 4-methyl-17 $\beta$ -[(2,4-dichlorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;

- (52) 4-methyl-17 $\beta$ -[(3-fluorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (53) 4-methyl-17β-[(4-fluorophenyl)acetamido]-4-aza-5α-androst-1-ene-3-one;
- (54) 4-methyl-17 $\beta$ -[(2-methoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (55) 4-methyl-17 $\beta$ -[(3-methoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (56) 4-methyl-17 $\beta$ -[(2,5-dimethoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (57) 4-methyl-17 $\beta$ -[(3,5-difluorophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (58) 4-methyl-17 $\beta$ -[(3-nitrophenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (59) 4-methyl-17 $\beta$ -(tetrahydrofuran-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (60) 4-methyl-17 $\beta$ -(tetrahydrofuran-3-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (61) 4-methyl-17β-(4-ethyl-pyridin-2-yl-amido)-4-aza-5α-androst-1-ene-3-one;
- (62) 4-methyl-17 $\beta$ -(3-methyl-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (63) 4-methyl-17 $\beta$ -(3-bromo-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (64) 4-methyl-17 $\beta$ -(4-bromo-pyridin-2-yl-amido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (65) 4-methyl-17 $\beta$ -[(2-phenylcyclopropyl)amido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (66) 4-methyl- $17\beta$ -[(2-fluorophenyl)acetamido]-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (67) 4-methyl-17 $\beta$ -[(pyrid-2-yl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (68) 4-methyl-17 $\beta$ -[(pyrid-3-yl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (69) 4-methyl-17 $\beta$ -[(4-methoxyphenyl)acetamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (70) 4-methyl-17β-[3-(2-fluorophenyl)propionamido]-4-aza-5α-androst-1-ene-3-one;
- (71) 4-methyl-17 $\beta$ -[3-(4-fluorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (72) 4-methyl-17 $\beta$ -[3-(4-rifluoromethylphenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3- one;
- (73) 4-methyl-17β-[3-(2-chlorophenyl)propionamido]-4-aza-5α-androst-1-ene-3-one;
- (74) 4-methyl-17β-[3-(3-chlorophenyl)propionamido]-4-aza-5α-androst-1-ene-3-one;
- (75) 4-methyl-17 $\beta$ -[3-(4-chlorophenyl)propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (76) 4-methyl- $17\beta$ -[2-trifluoromethylcinnamido]-4-aza- $5\alpha$ -androst-1-ene-3-one;
- (77) 4-methyl-17 $\beta$ -[2-chlorocinnamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (78) 4-methyl-17 $\beta$ -[2-fluorocinnamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (79) 4-methyl-17β-[4-(2,5-dichlorophenyl)butanamido]-4-aza-5α-androst-1-ene-3-one;
- (80) 4-methyl-17β-[4-(2-nitrophenyl)butanamido]-4-aza-5α-androst-1-ene-3-one;
- (81) 4-methyl-17β-[4-(3,4-dimethoxyphenyl)butanamido]-4-aza-5α-androst-1-ene-3-one;
- (82) 4-methyl-17 $\beta$ -[propionamido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (83) 4-methyl-17 $\beta$ -[butyramido]-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (84) 4-methyl-17β-[(2-methyl)cyclopropamido]-4-aza-5α-androst-1-ene-3-one;
- (85) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -phenyl ester;

Case No.: 20880P

- Page 39
- (86) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-chlorophenyl ester;$
- (87) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-nitrophenyl ester;$
- (88) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-methylphenyl ester;$
- (89) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-bromophenyl ester;$
- (90) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-fluorophenyl ester;$
- (91) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-methoxophenyl ester;$
- (92) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-nitrophenyl ester;$
- (93) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-naphthyl ester;$
- (94) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-trifluoromethylphenyl ester;$
- (95) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -ethyl ester;
- (96) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -benzyl ester;
- (97) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2,2,2-trifluoroethyl ester;$
- (98) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-methoxyethyl ester;$
- (99) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-(2,2-dimethylpropy)$  ester;
- (100) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-fluoroethyl ester;$
- (101) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]$ -allyl ester;
- (102) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-methyl ester;$
- (103) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-propynoic ester;$
- (104) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-(2-methyl-2-butyl)$  ester:
- (105) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-(trifluoromethyl)phenyl ester;$
- (106) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-(trifluoromethyl)phenyl ester;$
- (107) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-fluorophenyl ester;$
- (108) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-fluorophenyl ester;$
- (109) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-(2-hydroxy-1-ethyl)$  ester;
- (110) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-methoxyphenyl ester;$
- (111) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-methoxyphenyl ester;$
- (112) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-ethoxyphenyl ester;$

Case No.: 20880P

- (113) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-ethoxyphenyl ester;$
- (114) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-ethoxyphenyl ester;$
- (115) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-chlorophenyl ester;$
- (116) Carbamic acid, [(5α,17β)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-chlorophenyl ester;
- (117) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-3-(trifluoromethoxy)phenyl ester;$
- (118) Carbamic acid,  $[(5\alpha,17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-4-(trifluoromethoxy)phenyl ester;$
- (119) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-2-propyl ester;$
- (120) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-propyl ester;$
- (121) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-butyl ester;$
- (122) Carbamic acid,  $[(5\alpha, 17\beta)-3-oxo-4-methyl-azaandrost-1-ene-17-yl]-1-hexyl ester;$
- (123) 4-methyl-17 $\beta$ -(phenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (124) 4-methyl-17β-(2-trifluoromethylphenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (125) 4-methyl-17β-(3-trifluoromethylphenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (126) 4-methyl-17 $\beta$ -(2-chlorophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (127) 4-methyl-17 $\beta$ -(3-chlorophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (128) 4-methyl-17β-(2-trifluoromethoxyphenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (129) 4-methyl-17β-(2-cyanophenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (130) 4-methyl-17β-(4-methoxyphenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (131) 4-methyl-17 $\beta$ -(3-bromo-5--methoxyphenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (132) 4-methyl-17 $\beta$ -(8-quinolylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (133) 4-methyl-17β-(3-cyanophenylsulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (134) 4-methyl-17 $\beta$ -(4-chlorophenylsulfonamido)-4-aza-5 $\alpha$ -androst-1-ene-3-one;
- (135) 4-methyl-17β-[(2-methylsufonyl)phenyl]sulfonamido)-4-aza-5α-androst-1-ene-3-one;
- (136) N- $[(5\alpha, 17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- phenyl urea;
- (137) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2-trifluoromethyl)phenyl urea;
- (138) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (3-trifluoromethyl)phenyl urea;
- (139) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- 3-chlorophenyl urea;
- (140) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (4-chloro-2-trifluoromethylphenyl) urea;
- (141) N- $[(5\alpha, 17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- 3-acetylphenyl urea;
- (142) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (5-chloro-2-trifluoromethylphenyl) urea;

- (143) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2,4-[bistrifluoromethyl]phenyl) urea;
- (144) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (3,4-difluorophenyl) urea;
- (145) N-[ $(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2,3-dichlorophenyl) urea;
- (146) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2,4-dichlorophenyl) urea;
- (147)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (3,4-dichlorophenyl) urea;$
- (148)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-2-chlorophenyl) urea;$
- (149) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (2-chloro-5-trifluoromethylphenyl) urea;
- (150) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (4-chloro-3-trifluoromethylphenyl) urea;
- (151) N-[(5α,17β)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-(4-trifluoromethyl)phenyl urea;
- (152) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-(2,3-dimethylphenyl) urea;
- (153)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-methyl urea;$
- (154)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-ethyl urea;$
- (155)  $N-[(5\alpha,17\beta)-4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-dimethyl urea;$
- (156) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-diethyl urea;
- (157) N- $[(5\alpha,17\beta)$ -4-methyl-3-oxo-4-azaandrost-1-en-17-yl] urea;
  - (147) N-[(5I,174) 4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'- (3,4-dichlorophenyl) urea;
  - (148) N [(5I,170) 4 methyl 3-oxo 4-azaandrost-1-en-17-yl]-N'-2-ehlorophenyl) urea;
  - (149) N [(5I,170) 4 methyl-3 oxo 4 azaandrost 1 en 17 yl] N' (2 chloro 5 trifluoromethylphenyl) urea;
  - (150) N-[(5I,170) 4-methyl-3-oxo 4-azaandrost 1-en-17-yl]-N'- (4-chloro-3-trifluoromethylphenyl) urea;
  - (151) N-[(5I,170) 4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-(4-trifluoromethyl)phenyl urea;
  - (152) N-[(5I,170) 4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N' (2,3-dimethylpheny)
  - (153) N-[(5I,170) 4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-methyl-urea;
  - (154) N [(51,178) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' ethyl urea;
  - (155) N [(5I,178) 4 methyl 3 oxo 4 azaandrost 1 en 17 yl] N' dimethyl urea;
  - (156) N-[(5I,170) 4-methyl-3-oxo-4-azaandrost-1-en-17-yl]-N'-diethyl-urea;

Case No.: 20880P

Page 42

(157) N [(5I,170) 4 methyl-3-oxo 4-azaandrost-1-en-17-yl] urea; and pharmaceutically acceptable salts thereof.

- 16. (**Original**) A composition comprising a compound according to Claim 14 and a pharmaceutically acceptable carrier.
- 17. (Original) The composition according to Claim 16 additionally comprising a bone-strengthening agent selected from:
- (a) estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative,
- (b) a bisphosphonate,
- (c) an antiestrogen or a selective estrogen receptor modulator,
- (d) an osteoclast integrin inhibitor,
- (e) a cathepsin K inhibitor,
- (f) an HMG-CoA reductase inhibitor,
- (g) an osteoclast vacuolar ATPase inhibitor,
- (h) an antagonist of VEGF binding to osteoclast receptors,
- (i) a peroxisome proliferator-activated receptor  $\gamma$ ,
- (j) calcitonin,
- (k) a calcium receptor antagonist,
- (l) parathyroid hormone,
- (m) a growth hormone secretagogue,
- (n) human growth hormone,
- (o) insulin-like growth factor,
- (p) a P-38 protein kinase inhibitor,
- (q) bone morphogenic protein,
- (r) an inhibitor of BMP antagonism,
- (s) a prostaglandin derivative,
- (t) vitamin D or vitamin D derivative,
- (u) vitamin K or vitamin K derivative,
- (v) ipriflavone,
- (w) fluoride salts, and
- (x) dietary calcium supplement.

Case No.: 20880P Page 43

18. (**Original**) The pharmaceutical composition according to Claim 16, additionally comprising 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt, trihydrate.

## 19. (Cancelled) The use of a compound of structural formula I:

wherein:

"a" and "b" are independently selected from a single bond and a double bond;

X is selected from:

- (A) -C(O)-,
- (B) -C(O)-O-,
- (C)  $-C(O)-N(R^7)$ -,and
- (D)  $-S(O)_{n}$ -;

R1 is selected from:

- (A)  $C_{1-3}$  alkyl,
- (B) C<sub>2-3</sub> alkenyl,
- (C) C<sub>3-6</sub> cycloalkyl,
- (D) C<sub>1-3</sub> alkyl wherein one or more of the hydrogen atoms has been replaced with a fluorine atom,
- (E) aryl, and
- (F) aryl-C<sub>1-3</sub> alkyl;

R<sup>2</sup> is selected from:

- (A) aryl, either unsubstituted or substituted with one to three substituents selected from:
  - (1) halogen,
  - (2) aryl,
  - (3)  $C_{1-8}$  alkyl,

Case No.: 20880P

- (4) C<sub>3-8</sub> cycloalkyl,
- (5) C<sub>3-8</sub> cycloheteroalkyl,
- (6) aryl C<sub>1-6</sub>alkyl,
- (7) amino C<sub>0</sub>-6alkyl,
- (8) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (9) (C<sub>1-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (10) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (11) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (12)  $C_{1-6}$  alkylthio,
- (13) aryl C<sub>0</sub>-6alkylthio,
- (14) C<sub>1-6</sub> alkylsulfinyl,
- (15) aryl C<sub>0</sub>-6alkylsulfinyl,
- (16) C<sub>1-6</sub> alkylsulfonyl,
- (17) aryl C<sub>0</sub>-6alkylsulfonyl,
- (18)  $C_{1-6}$  alkoxy  $C_{0-6}$  alkyl,
- (19) aryl C<sub>0-6</sub> alkoxy C<sub>0-6</sub>alkyl,
- (20) hydroxycarbonyl C<sub>0-6</sub>alkyl,
- (21) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (22) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (24) hydroxy C<sub>0</sub>-6alkyl,
- (25) cyano,
- (26) nitro,
- (27) perfluoroC<sub>1-4</sub>alkyl,
- (28) perfluoroC<sub>1</sub>-4alkoxy,
- (29) C<sub>1-6</sub> alkylcarbonyloxy,
- (30) aryl C<sub>0-6</sub>alkylcarbonyloxy,
- (31) alkyl C<sub>1-6</sub> carbonylamino,
- (32) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (33) C<sub>1-6</sub> alkylsulfonylamino,
- (34) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (35) C<sub>1-6</sub> alkoxycarbonylamino,
- (36) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (37) C<sub>1-6</sub>alkylaminocarbonylamino,

Case No.: 20880P

- (38) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (39) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (40) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (C<sub>1</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy,
- (42) C<sub>0-6</sub> alkyl carbonyl C<sub>0-6</sub> alkyl,
- (43) aryl C<sub>0-6</sub> alkyl carbonyl C<sub>0-6</sub> alkyl, and
- (44) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy;
- (B) C<sub>1-8</sub> alkyl, unsubstituted or substituted with one to three substituents independently selected from:
  - (1) halogen,
  - (2)  $C_{1-8}$  alkyl,
  - (3) C<sub>3-8</sub> cycloalkyl,
  - (4) C<sub>3-8</sub> cycloheteroalkyl,
  - (5) amino,
  - (6) C<sub>1-6</sub> alkylamino,
  - (7) (C<sub>1-6</sub> alkyl)<sub>2</sub>amino,
  - (8) aryl C<sub>0-6</sub> alkylamino,
  - (9) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino,
  - (10) C<sub>1-6</sub> alkylthio,
  - (11) aryl C<sub>0</sub>-6alkylthio,
  - (12) C<sub>1-6</sub> alkylsulfinyl,
  - (13) aryl C<sub>0</sub>-6alkylsulfinyl,
  - (14) C<sub>1-6</sub> alkylsulfonyl,
  - (15) aryl C<sub>0-6</sub>alkylsulfonyl,
  - (16)  $C_{1-6}$  alkoxy,
  - (17) aryl C<sub>0-6</sub> alkoxy,
  - (18) hydroxycarbonyl,
  - (19) C<sub>1-6</sub> alkoxycarbonyl,
  - (20) aryl C<sub>0-6</sub> alkoxycarbonyl,
  - (21) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
  - (22) hydroxy,
  - (23) cyano,
  - (24) nitro,
  - (25) perfluoroC<sub>1-4</sub>alkyl,

Case No.: 20880P

- (26) perfluoroC<sub>1-4</sub>alkoxy,
- (27) oxo,
- (28) C<sub>1-6</sub> alkylcarbonyloxy,
- (29) aryl C<sub>0-6</sub>alkylcarbonyloxy,
- (30) alkyl C<sub>1-6</sub> carbonylamino,
- (31) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (32) C<sub>1-6</sub> alkylsulfonylamino,
- (33) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (34) C<sub>1-6</sub> alkoxycarbonylamino,
- (35) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (36) C<sub>1-6</sub>alkylaminocarbonylamino,
- (37) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (38) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (39) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (41) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy, and
- (42) spiro-C3-8cycloalkyl;
- (C) perfluoroC<sub>1-6</sub> alkyl,
- (D) aryl-C<sub>1-6</sub> alkyl-, wherein aryl is unsubstituted or substituted with 1 to 3 substituents independently selected from:
  - (1) halogen,
  - (2)  $C_{1-8}$  alkyl,
  - (3) C<sub>3-8</sub> cycloalkyl,
  - (4) aryl,
  - (5) aryl  $C_{1-3}$  alkyl-,
  - (6) amino,
  - (7)  $amino C_{1-6} alkyl-$ ,
  - (8) C<sub>1-3</sub> acylamino,
  - (9) C<sub>1-3</sub> acylamino C<sub>1-6</sub> alkyl,
  - (10) C<sub>1-6</sub> alkylamino,
  - (11)  $C_{1-6}$  alkylamino  $C_{1-6}$  alkyl,
  - (12) di(C<sub>1-6</sub>) alkylamino,
  - (13)  $di(C_{1-6})$  alkylamino- $C_{1-6}$  alkyl,
  - (14)  $C_{1-4}$  alkoxy,

Case No.: 20880P

Page 47

- (15) C<sub>1-4</sub> alkylthio,
- (16) C<sub>1-4</sub> alkylsulfinyl,
- (17) C<sub>1-4</sub> alkylsulfonyl,
- (18)  $C_{1-4}$  alkoxy  $C_{1-6}$  alkyl,
- (19) hydroxycarbonyl,
- (20) hydroxycarbonyl C<sub>1-6</sub> alkyl,
- (21) C<sub>1-5</sub> alkoxycarbonyl,
- (22) C<sub>1-3</sub> alkoxycarbonyl C<sub>1-6</sub> alkyl,
- (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (24) hydroxy,
- (25) hydroxy C<sub>1-6</sub> alkyl,
- (26) cyano,
- (27) nitro,
- (28) trifluoromethyl,
- (29) trifluoromethoxy,
- (30) C<sub>1-5</sub> alkylcarbonyloxy;

## and wherein alkyl is substituted with one to three substituents selected from:

- (1) halogen,
- (2) C<sub>3-8</sub> cycloalkyl,
- (3) C<sub>3-8</sub> cycloheteroalkyl,
- (4) amino,
- (5) C<sub>1-6</sub> alkylamino,
- (6) (C<sub>1-6</sub> alkyl)2amino,
- (7) aryl C<sub>0-6</sub> alkylamino,
- (8) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino,
- (9)  $C_{1-6}$  alkylthio,
- (10) aryl C<sub>0-6</sub> alkylthio,
- (11) C<sub>1-6</sub> alkylsulfinyl,
- (12) aryl C<sub>0</sub>-6alkylsulfinyl,
- (13) C<sub>1-6</sub> alkylsulfonyl,
- (14) aryl C<sub>0-6</sub> alkylsulfonyl,
- (15)  $C_{1-6}$  alkoxy,
- (16) aryl C<sub>0-6</sub> alkoxy,
- (17) hydroxycarbonyl,

Case No.: 20880P

Page 48

(18) C<sub>1-6</sub> alkoxycarbonyl,

١

- (19) aryl C<sub>0-6</sub> alkoxycarbonyl,
- (20) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (21) hydroxy,
- (22) cyano,
- (23) nitro,
- (24) trifluoroalkyl,
- (25) trifluoroalkoxy,
- (26) oxo,
- (27) C<sub>1-6</sub> alkylcarbonyloxy,
- (28) aryl C<sub>0-6</sub> alkylcarbonyloxy,
- (29) C<sub>1-6</sub> alkyl carbonylamino,
- (30) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (31) C<sub>1-6</sub> alkylsulfonylamino,
- (32) aryl C<sub>0-6</sub> alkylsulfonylamino,
- (33) C<sub>1-6</sub> alkoxycarbonylamino,
- (34) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (35) C<sub>1-6</sub> alkylaminocarbonylamino,
- (36) aryl C<sub>0-6</sub> alkylaminocarbonylamino,
- (37) (C<sub>1-6</sub> alkyl)<sub>2</sub> aminocarbonylamino,
- (38) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub> aminocarbonylamino,
- (39) (C<sub>1-6</sub> alkyl)<sub>2</sub> aminocarbonyloxy,
- (40) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub> aminocarbonyloxy, and
- (41) spiro-C<sub>3-8</sub> cycloalkyl;
- (E) C2-8 alkenyl, unsubstituted or substituted with one to three substituents independently selected from:
  - (1) halogen,
  - (2)  $C_{1-8}$  alkyl,
  - (3) C<sub>3-8</sub> cycloalkyl,
  - (4) C<sub>3-8</sub> cycloheteroalkyl,
  - (5) amino,
  - (6) C<sub>1-6</sub> alkylamino,
  - (7)  $(C_{1-6} \text{ alkyl})_{2}$ amino,
  - (8) aryl C<sub>0-6</sub> alkylamino,

Case No.: 20880P

- (9) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino,
- (10) C<sub>1-6</sub> alkylthio,
- (11) aryl C<sub>0</sub>-6alkylthio,
- (12) C<sub>1-6</sub> alkylsulfinyl,
- (13) aryl C<sub>0-6</sub>alkylsulfinyl,
- (14) C<sub>1-6</sub> alkylsulfonyl,
- (15) aryl C<sub>0-6</sub>alkylsulfonyl,
- (16) C<sub>1-6</sub> alkoxy,
- (17) aryl C<sub>0-6</sub> alkoxy,
- (18) hydroxycarbonyl,
- (19) C<sub>1-6</sub> alkoxycarbonyl,
- (20) aryl C<sub>0-6</sub> alkoxycarbonyl,
- (21) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (22) hydroxy,
- (23) cyano,
- (24) nitro,
- (25) perfluoroC<sub>1-4</sub>alkyl,
- (26) perfluoroC<sub>1-4</sub>alkoxy,
- (27) oxo,
- (28) C<sub>1-6</sub> alkylcarbonyloxy,
- (29) aryl C<sub>0</sub>-6alkylcarbonyloxy,
- (30) alkyl C<sub>1-6</sub> carbonylamino,
- (31) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (32) C<sub>1-6</sub> alkylsulfonylamino,
- (33) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (34) C<sub>1-6</sub> alkoxycarbonylamino,
- (35) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (36) C<sub>1-6</sub>alkylaminocarbonylamino,
- (37) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (38) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (39) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (40) (C<sub>1</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy,
- (41) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy, and
- (42) spiro-C3-8cycloalkyl;

Case No.: 20880P

- (F) aryl C<sub>2-8</sub> alkenyl, wherein aryl is unsubstituted or substituted with one to three substituents independently selected from:
  - (1) halogen,
  - (2)  $C_{1-8}$  alkyl,
  - (3) C<sub>3-8</sub> cycloalkyl,
  - (4) aryl,
  - (5)  $aryl C_{1-3} alkyl-$ ,
  - (6) amino,
  - (7) amino  $C_{1-6}$  alkyl-,
  - (8) C<sub>1-3</sub> acylamino,
  - (9) C<sub>1-3</sub> acylamino C<sub>1-6</sub> alkyl,
  - (10) C<sub>1-6</sub> alkylamino,
  - (11)  $C_{1-6}$  alkylamino  $C_{1-6}$  alkyl,
  - (12) di(C<sub>1-6</sub>) alkylamino,
  - (13)  $di(C_{1-6})$  alkylamino- $C_{1-6}$  alkyl,
  - (14)  $C_{1-4}$  alkoxy,
  - (15)  $C_{1-4}$  alkylthio,
  - (16) C<sub>1-4</sub> alkylsulfinyl,
  - (17) C<sub>1-4</sub> alkylsulfonyl,
  - (18)  $C_{1-4}$  alkoxy  $C_{1-6}$  alkyl,
  - (19) hydroxycarbonyl,
  - (20) hydroxycarbonyl C<sub>1-6</sub> alkyl,
  - (21) C<sub>1-5</sub> alkoxycarbonyl,
  - (22) C<sub>1-3</sub> alkoxycarbonyl C<sub>1-6</sub> alkyl,
  - (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
  - (24) hydroxy,
  - (25) hydroxy C<sub>1-6</sub> alkyl,
  - (26) cyano,
  - (27) nitro,
  - (28) trifluoromethyl,
  - (29) trifluoromethoxy, and
  - (30) C<sub>1-5</sub> alkylcarbonyloxy;
- (G) C<sub>3-8</sub> cycloalkyl, either unsubstituted or substituted with one to 3 substituents selected from:

Case No.: 20880P

- (1) halogen,
- (2) aryl,
- (3)  $C_{1-8}$  alkyl,
- (4) C<sub>3-8</sub> cycloalkyl,
- (5) C<sub>3-8</sub> cycloheteroalkyl,
- (6) aryl C<sub>1</sub>-6alkyl,
- (7) amino C<sub>0</sub>-6alkyl,
- (8) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (9) (C<sub>1-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (10) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (11) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (12)  $C_{1-6}$  alkylthio,
- (13) aryl C<sub>0</sub>-6alkylthio,
- (14) C<sub>1-6</sub> alkylsulfinyl,
- (15) aryl C<sub>0-6</sub>alkylsulfinyl,
- (16) C<sub>1-6</sub> alkylsulfonyl,
- (17) aryl C<sub>0</sub>-6alkylsulfonyl,
- (18) C<sub>1-6</sub> alkoxy C<sub>0-6</sub>alkyl,
- (19) aryl C<sub>0-6</sub> alkoxy C<sub>0-6</sub>alkyl,
- (20) hydroxycarbonyl C<sub>0-6</sub>alkyl,
- (21) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (22) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (24) hydroxy C<sub>0-6</sub>alkyl,
- (25) cyano,
- (26) nitro,
- (27) perfluoroC<sub>1-4</sub>alkyl,
- (28) perfluoroC<sub>1-4</sub>alkoxy,
- (29) oxo,
- (30) C<sub>1-6</sub> alkylcarbonyloxy,
- (31) aryl C<sub>0</sub>-6alkylcarbonyloxy,
- (32) alkyl C<sub>1-6</sub> carbonylamino,
- (33) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (34) C<sub>1-6</sub> alkylsulfonylamino,

Case No.: 20880P

- (35) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (36) C<sub>1-6</sub> alkoxycarbonylamino,
- (37) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (38) C<sub>1-6</sub>alkylaminocarbonylamino,
- (39) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (42) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (43) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy,
- (44) C 0-6 alkylcarbonly C 0-6 alky, and
- (45) spiro-C3-8cycloalkyl;
- (H) cycloheteroalkyl, unsubstituted or substituted with one to three substituents selected from:
  - (1) halogen,
  - (2) aryl,
  - (3)  $C_{1-8}$  alkyl,
  - (4) C<sub>3-8</sub> cycloalkyl,
  - (5) C<sub>3-8</sub> cycloheteroalkyl,
  - (6) aryl C<sub>1-6</sub>alkyl,
  - (7) amino C<sub>0</sub>-6alkyl,
  - (8) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
  - (9)  $(C_{1-6} \text{ alkyl})_{2}$ amino  $C_{0-6}$ alkyl,
  - (10) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
  - (11) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
  - (12)  $C_{1-6}$  alkylthio,
  - (13) aryl C<sub>0-6</sub>alkylthio,
  - (14) C<sub>1-6</sub> alkylsulfinyl,
  - (15) aryl C<sub>0</sub>-6alkylsulfinyl,
  - (16) C<sub>1-6</sub> alkylsulfonyl,
  - (17) aryl C<sub>0</sub>-6alkylsulfonyl,
  - (18) C<sub>1-6</sub> alkoxy C<sub>0-6</sub>alkyl,
  - (19) aryl C<sub>0-6</sub> alkoxy C<sub>0-6</sub>alkyl,
  - (20) hydroxycarbonyl C<sub>0-6</sub>alkyl,
  - (21) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,

Case No.: 20880P

Page 53

- (22) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (24) hydroxy C<sub>0-6</sub>alkyl,
- (25) cyano,
- (26) nitro,
- (27) perfluoroC<sub>1-4</sub>alkyl,
- (28) perfluoroC<sub>1-4</sub>alkoxy,
- (29) oxo,
- (30) C<sub>1-6</sub> alkylcarbonyloxy,
- (31) aryl C<sub>0</sub>-6alkylcarbonyloxy,
- (32) alkyl C<sub>1-6</sub> carbonylamino,
- (33) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (34) C<sub>1-6</sub> alkylsulfonylamino,
- (35) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (36) C<sub>1-6</sub> alkoxycarbonylamino,
- (37) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (38) C<sub>1-6</sub>alkylaminocarbonylamino,
- (39) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (42) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (43) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy, and
- (44) spiro-C3-8cycloalkyl;

provided that any heteroatom substituent is bonded to a carbon atom in the cycloheteroalkyl ring;

R<sup>3</sup> is selected from H, perfluoro C<sub>1-8</sub> alkyl, and C<sub>1-8</sub> alkyl, unsubstituted or substituted with one to three halogen atoms, or R<sup>2</sup> and R<sup>3</sup>, together with the nitrogen atom, and the "X" moiety to which they are attached, form a 5- to 7-membered heterocyclic ring, optionally containing one or two additional heteroatoms selected from N, S, and O, optionally having one or more degrees of unsaturation, optionally fused to a 6-membered heteroaromatic or aromatic ring, either unsubstituted or substituted with one to three substituents selected from:

- (1) halogen,
- (2) aryl,
- (3)  $C_{1-8}$  alkyl,

Case No.: 20880P

- (4) C<sub>3-8</sub> cycloalkyl,
- (5) C<sub>3-8</sub> cycloheteroalkyl,
- (6) aryl C<sub>1</sub>-6alkyl,
- (7)  $amino C_{0-6}alkyl$ ,
- (8) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (9) (C<sub>1-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (10) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (11) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (12)  $C_{1-6}$  alkylthio,
- (13) aryl C<sub>0</sub>-6alkylthio,
- (14) C<sub>1-6</sub> alkylsulfinyl,
- (15) aryl C<sub>0</sub>-6alkylsulfinyl,
- (16) C<sub>1-6</sub> alkylsulfonyl,
- (17) aryl C<sub>0</sub>-6alkylsulfonyl,
- (18)  $C_{1-6}$  alkoxy  $C_{0-6}$  alkyl,
- (19) aryl C<sub>0-6</sub> alkoxy C<sub>0-6</sub>alkyl,
- (20) hydroxycarbonyl C<sub>0-6</sub>alkyl,
- (21) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (22) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (23) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,
- (24) hydroxy C<sub>0-6</sub>alkyl,
- (25) cyano,
- (26) nitro,
- (27) perfluoroC<sub>1</sub>-4alkyl,
- (28) perfluoroC<sub>1-4</sub>alkoxy,
- (29) oxo,
- (30) C<sub>1-6</sub> alkylcarbonyloxy,
- (31) aryl C<sub>0</sub>-6alkylcarbonyloxy,
- (32) C<sub>1-6</sub> alkyl carbonylamino,
- (33) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (34) C<sub>1-6</sub> alkylsulfonylamino,
- (35) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (36) C<sub>1-6</sub> alkoxycarbonylamino,
- (37) aryl C<sub>0-6</sub> alkoxycarbonylamino,

Case No.: 20880P

Page 55

- (38) C<sub>1-6</sub>alkylaminocarbonylamino,
- (39) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (40) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (42) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (43) (aryl C<sub>0-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy, and
- (44) spiro-C3-8cycloalkyl,

provided that any heteroatom substituent is bonded to a carbon atom in the heterocyclic ring;

## $R^4$ and $R^5$ are each independently selected from

- (1) hydrogen,
- (2) halogen,
- (3) aryl,
- (4)  $C_{1-8}$  alkyl,
- (5) C<sub>3-8</sub> cycloalkyl,
- (6) C<sub>3-8</sub> cycloheteroalkyl,
- (7) aryl C<sub>1</sub>-6alkyl,
- (8) amino C<sub>0</sub>-6alkyl,
- (9) C<sub>1-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (10)  $(C_{1-6} \text{ alkyl})_{2}$ amino  $C_{0-6}$ alkyl,
- (11) aryl C<sub>0-6</sub> alkylamino C<sub>0-6</sub>alkyl,
- (12) (aryl C<sub>0-6</sub> alkyl)<sub>2</sub>amino C<sub>0-6</sub>alkyl,
- (13) C<sub>1-6</sub> alkylthio,
- (14) aryl C<sub>0</sub>-6alkylthio,
- (15) C<sub>1-6</sub> alkylsulfinyl,
- (16) aryl C<sub>0-6</sub>alkylsulfinyl,
- (17) C<sub>1-6</sub> alkylsulfonyl,
- (18) aryl C<sub>0</sub>-6alkylsulfonyl,
- (19) C<sub>1-6</sub> alkoxy C<sub>0-6</sub>alkyl,
- (20) aryl  $C_{0-6}$  alkoxy  $C_{0-6}$ alkyl,
- (21) hydroxycarbonyl C<sub>0-6</sub>alkyl,
- (22) C<sub>1-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (23) aryl C<sub>0-6</sub> alkoxycarbonyl C<sub>0-6</sub>alkyl,
- (24) hydroxycarbonyl C<sub>1-6</sub> alkyloxy,

Case No.: 20880P

Page 56

- (25) hydroxy C<sub>0-6</sub>alkyl,
- (26) cyano,
- (27) nitro,
- (28) perfluoroC<sub>1</sub>-4alkyl,
- (29) perfluoroC<sub>1-4</sub>alkoxy,
- (30) C<sub>1-6</sub> alkylcarbonyloxy,
- (31) aryl C<sub>0</sub>-6alkylcarbonyloxy,
- (32) C<sub>1-6</sub> alkylcarbonylamino,
- (33) aryl C<sub>0-6</sub> alkylcarbonylamino,
- (34) C<sub>1-6</sub> alkylsulfonylamino,
- (35) aryl C<sub>0</sub>-6alkylsulfonylamino,
- (36) C<sub>1-6</sub> alkoxycarbonylamino,
- (37) aryl C<sub>0-6</sub> alkoxycarbonylamino,
- (38) C<sub>1-6</sub>alkylaminocarbonylamino,
- (39) aryl C<sub>0</sub>-6alkylaminocarbonylamino,
- (40) (C<sub>1</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (41) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonylamino,
- (42) (C<sub>1-6</sub>alkyl)<sub>2</sub> aminocarbonyloxy,
- (43) (aryl C<sub>0</sub>-6alkyl)<sub>2</sub> aminocarbonyloxy, and
- (44) spiro-C3-8cycloalkyl;

or, R<sup>4</sup> and R<sup>5</sup> together form an oxo group or =CH-R<sup>6</sup> or a spiro C 3-7 cycloalkyl ring substituted with R<sup>6</sup>;

R<sup>6</sup> is selected from hydrogen and C<sub>1-4</sub> alkyl;

 $R^7$  is selected from hydrogen, perfluoro  $C_{1-8}$  alkyl, and  $C_{1-8}$  alkyl, unsubstituted or substituted with one to three halogen atoms.

n is selected from: 0, 1, and 2;

and pharmaceutically acceptable salts thereof;

for the preparation of a medicament useful for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation.

20. (Cancelled) The use according to Claim 19 wherein modulating the androgen receptor comprises agonizing the androgen receptor in a patient in need thereof.

Case No.: 20880P

Page 57

21. (Cancelled) The use according to Claim 19 wherein modulating the androgen receptor is useful in treating a condition caused by androgen deficiency or which can be ameliorated by androgen administration selected from: osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, HIV-wasting, cancer cachexia, bone fracture, bone damage following bone reconstructive surgery, muscular dystrophies, sarcopenia, frailty, aging skin, male hypogonadism, post-menopausal symptoms in women, female sexual dysfunction, premature ovarian failure, autoimmune disease, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, arthritis and joint repair.